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C. difficile infection is a deadly disease that is influenced by the microbiome. In a recent article in Nature,
Buffie et al. (2014) demonstrate that the ability of C. scindens to synthesize secondary bile acids is crucial
to providing resistance to C. difficile infection.Our overuse of antibiotics has led to
numerous detrimental health outcomes,
including an increasing number of
C. difficile infections (CDIs). In the United
States, more than 14,000 individuals
die annually from CDIs (Dubberke, 2012),
costing greater than $3 billion dollars
annually. The most common treatments
for CDI are antibiotics such as vancomy-
cin, metronidazole, and fidaxomicin, but
they do not eradicate C. difficile spores
and can cause collateral damage by
killing commensal bacteria that compete
with and potentially inhibit the growth of
C. difficile. Consequently, some individ-
uals become refractory to antibiotics and
have recurrent CDI. On a brighter note,
the use of fecal microbiota transplants
(FMTs) as a therapy has been very effec-
tive in the treatment of relapsing CDI
(Sofi et al., 2013). Yet a major gap exists
in our understanding of the interaction
between the host-microbe relationship
and the microbial factors that confer
resistance and susceptibility to CDI. Buf-
fie et al. (2014) address this issue in their
recent Nature paper, using a combination
of human, murine, and mathematical
models to identify a specific bacterium
and enzyme that confers resistance to
antibiotic-induced CDI.
To recapitulate the effect of antibiotics
associated with CDI in a murine model,
Buffie et al. (2014) treated mice with anti-
biotics (clindamycin, ampicillin, or enro-
floxacin) followed by a gavage challenge
with C. difficile. Each antibiotic challenge
not only induced a shift in the microbiome
structure but also conferred differential
resistance to C. difficile, with enrofloxacin
offering lasting and complete protectionand clindamycin offering minimal protec-
tion. Although beta diversity (between
samples) gradually returned to that of
an antibiotic-naive state, some animals
that were resistant also had low alpha
diversity (within sample), indicating that
specific microbiota were necessary to
maintain resistance. To identify these
resistance-conferring species, the au-
thors correlated species abundance with
C. difficile resistance and found several
candidates, including C. scindens. While
C. scindens, a member of the family
Lachnospiracea, is clearly a key player
in the resistance against germination of
C. difficile spores, others have shown
that members of the Bacteroides and Ru-
minococcaceae families are associated
with CDI resistance in humans, of which
Lachnospiracea and Ruminococcaceae
are butyrate producers (Lawley et al.,
2012; Schubert et al., 2014). C. scindens
is also a member of the Clostridium XIVa
clade, which has been shown to aid in
the expansion of anti-inflammatory Treg
cells via butyrate production. Butyrate is
the primary fuel for enterocytes and can
resolve colitis (Furusawa et al., 2013),
and loss of butyrate is also associated
with CDI. Future studies will determine
if changes in butyrate levels, Treg cells,
and other downstream inflammatory me-
diators contribute to resistance against
C. difficile as the result of microbial and
bile acid changes.
Although humans and mice share a
similar microbial core, there are notable
differences. With this limitation in mind,
Buffie et al. (2014) employed the use
of patients undergoing allogeneic he-
matopoietic stem-cell transplants, whichCell Metabolismincluded the use of antibiotics in some
cases, to compare microbial changes
and resistance to CDI. Using a novel
network modeling approach, they were
able to identify species with the highest
positive correlation with resistance in
both humans and mice, which included
C. scindens. They tested the causal rela-
tionship between C. scindens and CDI
resistance using antibiotic-pretreated
mice inoculatedwith either a four-bacteria
suspension, including C. scindens, iden-
tified from the resistant network, or
C. scindens alone. Adoptive transfer with
all four bacteria or C. scindens alone
conferred improved survival over PBS
control, reduced C. difficile growth, and
greater weight gain without changes in
alpha diversity.
Bacteria live not in isolation but in com-
munities defined by their environment.
These bacteria are influenced by one
another as well as by the host. This point
has been well documented in several
model systems, which demonstrate that
bacteria use small molecules such as
bile acids to communicate and survive
(Sofi et al., 2013). Bile acids in the cecum
are deconjugated by microbial-derived
bile salt hydrolases into primary bile
acids such as cholate (Ridlon et al.,
2006), which can stimulate the germina-
tion of C. difficile spores (Francis et al.,
2013). Other bacterial species, including
C. scindens, further modify the primary
bile acids via 7a-dehydroxylation to sec-
ondary bile acids such as deoxycholic
acid (Ridlon et al., 2006; Theriot et al.,
2014). Though data have suggested that
specific microbes can alter the concen-
tration of these germinants, the specific21, January 6, 2014 ª2015 Elsevier Inc. 9
Figure 1. S. scindens and Secondary Bile Acids Inhibit C. difficile Growth
(Left) In the absence of antibiotics, the gutmicrobial community is diverse and includes bacteria such asS. scindens that convert primary bile acids into secondary
bile acids, which, in turn, inhibits the growth ofC. difficile. (Right) Broad-spectrum antibiotics diminish the diversity of the gut microbial community. Loss of certain
bacteria such asC. scindens results in reduced production of secondary bile acids and increased growth of C. difficile. Additionally, accumulation of primary bile
acids leads to increased spore germination of C. difficile.
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Previewshost-microbial mechanism is not well
understood. Based on the ability of
C. scindens to synthesize secondary bile
acids via expression of baiCD, Buffie and
colleagues utilized the microbial abun-
dance data from theirmodel of CDI to infer
abundance of this gene. They demon-
strated that abundance of the secondary
bile acid gene family was higher in resis-
tant animals and correlated with pres-
ence of the bai operon. Furthermore,
they showed that engraftment with
C. scindens, alone or in combination with
several other bacterial species, restored
levels of a secondary bile acid (deoxy-
cholic acid) that protects against CDI
(Figure 1), indicating the importance of
our microbiota in maintaining bile acid ho-
meostasis and resistance to outgrowth of
pathogenic bacteria. Importantly, Buffie
et al. (2014) were able to demonstrate
that C. scindens requires bile salts to
confer resistance to CDI. These conclu-
sions are also supported by data from
Theriot et al. (2014), who show a decrease
in secondary bile acids after antibiotic
treatment in mice. Though deoxycholic
acid is likely produced from the action of
7a-dehydroxylating enzyme of baiCD of
C. scindens, it would be ideal to usebaiCD10 Cell Metabolism 21, January 6, 2014 ª201mutant C. scindens or a closely related
bacteriumwith low levels of 7a-dehydrox-
ylating activity (Ridlon et al., 2010) to un-
equivocally demonstrate that this enzyme
is essential for resistance to CDI.
In summary, Buffie et al. (2014) demon-
strate that an important mechanism of
the microbiome is to control pathogens
through bile acid homeostasis. Impor-
tantly, they show that the resistance-
conferring bacterium C. scindens is pre-
sent in both human and murine models
of CDI, which could have important
translational implications (Figure 1). For
instance, CDI treatment could utilize
narrow-spectrum antibiotics that spare
C. scindens. Alternatively, C. scindens
could be restored by including it as one
of the cultured bacteria used in synthetic
FMTs. This probiotic method, which
is already being used, prevents the het-
erogeneity of conventional FMTs and
excludes harmful viruses and antibiotic-
resistant bacteria. Overall, the current
work demonstrates the power of the mi-
crobiome as a tool to identify novel mech-
anisms of disease that could be used to
develop targeted antibiotics, probiotics,
and small molecule treatments for gastro-
intestinal diseases.5 Elsevier Inc.REFERENCES
Buffie, C.G., Bucci, V., Stein, R.R., McKenney,
P.T., Ling, L., Gobourne, A., No, D., Liu, H., Kinne-
brew, M., Viale, A., et al. (2014). Nature. Published
online October 22, 2014. http://dx.doi.org/10.
1038/nature13828.
Dubberke, E. (2012). J. Hosp. Med. 7 (Suppl 3 ),
S1–S4.
Francis, M.B., Allen, C.A., Shrestha, R., and Sorg,
J.A. (2013). PLoS Pathog. 9, e1003356.
Furusawa, Y.,Obata,Y., Fukuda,S., Endo, T.A.,Na-
kato, G., Takahashi, D., Nakanishi, Y., Uetake, C.,
Kato,K., Kato, T., et al. (2013).Nature504, 446–450.
Lawley, T.D., Clare, S., Walker, A.W., Stares, M.D.,
Connor, T.R., Raisen, C., Goulding, D., Rad, R.,
Schreiber, F., Brandt, C., et al. (2012). PLoS
Pathog. 8, e1002995.
Ridlon, J.M., Kang, D.J., and Hylemon, P.B. (2006).
J. Lipid Res. 47, 241–259.
Ridlon, J.M., Kang, D.J., and Hylemon, P.B. (2010).
Anaerobe 16, 137–146.
Schubert, A.M., Rogers, M.A., Ring, C., Mogle, J.,
Petrosino, J.P., Young, V.B., Aronoff, D.M., and
Schloss, P.D. (2014). mBiol. 5, e01021–01014.
Sofi, A.A., Silverman, A.L., Khuder, S., Garborg, K.,
Westerink, J.M., and Nawras, A. (2013). Scand. J.
Gastroenterol. 48, 266–273.
Theriot, C.M., Koenigsknecht, M.J., Carlson, P.E.,
Jr., Hatton, G.E., Nelson, A.M., Li, B., Huffnagle,
G.B., J, Z.L., and Young, V.B. (2014). Nat. Com-
mun. 5, 3114.
